PHARMACEUTICAL PREPARATIONS FOR TREATMENTS OF DISEASES AND DISORDERS OF THE BREAST
First Claim
1. A drug formulation comprising a drug selected from the group consisting of danazol, bromocriptine, and luteinizing hormone-releasing hormone (LHRH) analogues, in an amount effective to provide regional, not systemic, relief from benign diseases or disorders of the breast in a hydroalcoholic pharmaceutical carrier comprising a transdermal penetration enhancer to promote delivery of the drug across the stratum corneum.
2 Assignments
0 Petitions
Accused Products
Abstract
Formulations for topical or local administration of drugs directly to the breast or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the breast, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in the region to be treated with a reduction of side effects compared to those administered systemically. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion or foam.
-
Citations
26 Claims
- 1. A drug formulation comprising a drug selected from the group consisting of danazol, bromocriptine, and luteinizing hormone-releasing hormone (LHRH) analogues, in an amount effective to provide regional, not systemic, relief from benign diseases or disorders of the breast in a hydroalcoholic pharmaceutical carrier comprising a transdermal penetration enhancer to promote delivery of the drug across the stratum corneum.
- 12. A method for treating a disease or disorder of the breast, chest or underlying musculature comprising topically administering to a patient in need thereof a drug formulation comprising a drug selected from the group consisting of danazol, bromocriptine, and luteinizing hormone-releasing hormone (LHRH) analogues, in an amount effective to provide regional, not systemic, relief from benign diseases or disorders of the breast in a hydroalcoholic pharmaceutical carrier comprising a transdermal penetration enhancer to promote delivery of the drug across the stratum corneum.
Specification